The new edition of this book highlights the recent advances and state-of-the art in surgical and non-surgical management of thyroid cancer. Readers will learn about the latest advances and recommendations in the field, from molecular studies and biomarkers to the changing epidemiology, kinase inhibition in drug discovery and new surgical approaches, such as intra-operative neural monitoring and robotics. The management of differentiated thyroid cancer as well as childhood cancer, survivorship and clinical trial design and findings and how these fit into cancer management are discussed in detail.
This comprehensive volume provides an overview of the current world literature and outlines the practical aspects of management from world leaders in this field and helps clinicians and patients on practical matters. With a selection of authors from around the world it draws on international experience giving a global perspective to the topic. Following on from the success of the first edition, it uses a multidisciplinary, evidence-based approach centered on the patient, discussing guidelines and how these have improved the quality of care and outcomes.
This guide is aimed mainly at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons – Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, of course, patients.
• Draws on international experience across many disciplines offering a practical approach to the topic
• Examines the latest advances in surgical and non-surgical management
• Discusses molecular studies and translational research and how they have transformed the diagnosis and management of thyroid cancer
• Addresses current challenges and areas of controversy such as low risk thyroid cancer and papillary microcarcinoma
• Dr Ujjal Mallick, MBBS MS FRCPE (Hon) FRCP(Hon) FRCR Consultant Clinical Oncologist Formerly Consultant Oncologist and past Chair, Multidisciplinary thyroid cancer team (MDT), Freeman Hospital, Newcastle upon Tyne, UK, a centre of excellence for thyroid cancer. Chief Investigator of the first UK National Thyroid Cancer Trial -Hilo-( NEJM 2012) which helped modify international guidelines and practice and of the on-going second UK trial-IoN. One of the lead authors of the first UK National guideline. The MDT obtained many prestigious national awards including–Best NHS "Hospital Doctor" Oncology Team of the Year” Award 2007, Best Thyroid cancer MDT in NHS Peer Review 2011, first prize in NHS innovations award 2007 and others. He initiated an acclaimed MD clinic involving an expert thyroid cancer patient. Current interests are trials, biomarkers and guideline implementation.
• Dr Clive Harmer MB FRCR FRCP. Clinical Oncologist Consultant in Clinical Oncology at St. George’s Healthcare NHS Trust and The Royal Marsden NHS Trust (where he was head of the Thyroid unit) until August 2005. Recognized teacher of the University of London and Honorary Senior Lecturer at the Institute of Cancer Research.